FIB4 score is increased in severe preeclampsia

S. Özer, Hakan Güneş, A. Özer
{"title":"FIB4 score is increased in severe preeclampsia","authors":"S. Özer, Hakan Güneş, A. Özer","doi":"10.1515/tjb-2022-0214","DOIUrl":null,"url":null,"abstract":"Abstract Objectives This study aims to investigate how the fibrosis index based on four factors (FIB-4) is altered in preeclampsia and whether the FIB-4 score differs with respect to the severity of preeclampsia and the presence of fetal and maternal adverse outcomes. Methods One hundred and forty-two patients with mild preeclampsia (34.6 %), one hundred and ninety patients who have preeclampsia with severe features (46.2 %), and 79 healthy pregnant controls (19.2 %) were included in the study. Fetal adverse outcomes occurred in 40.1 %, and maternal adverse outcomes only appeared as neurological symptoms in 20.5 % of the preeclampsia patients. Results Healthy controls had significantly lower FIB-4 scores than women with mild preeclampsia, and women with mild preeclampsia had significantly lower FIB-4 scores than women who had preeclampsia with severe features (respectively 0.58±0.29 vs. 0.68±0.44 vs. 1.93±4.92, p=0.003). The FIB-4 scores of preeclampsia patients with neurologic symptoms and preeclampsia patients with fetal adverse events were found to be similar to preeclampsia patients who did not have these problems. In ROC curve analysis, FIB-4 scores ≥0.758 indicated the presence of neurologic symptoms in preeclampsia patients, with a sensitivity of 0.66 and a specificity of 0.66 (p=0.004). Conclusions To the best of our knowledge, this is the first study to establish the FIB-4 scores of preeclampsia patients and determine if FIB-4 scores change with respect to maternal and fetal adverse outcomes. Our findings suggest that FIB-4 might be used to predict pregnancies destined to be complicated with preeclampsia and preeclampsia patients who are more likely to experience maternal and fetal adverse outcomes.","PeriodicalId":23344,"journal":{"name":"Turkish Journal of Biochemistry","volume":"15 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Biochemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/tjb-2022-0214","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract Objectives This study aims to investigate how the fibrosis index based on four factors (FIB-4) is altered in preeclampsia and whether the FIB-4 score differs with respect to the severity of preeclampsia and the presence of fetal and maternal adverse outcomes. Methods One hundred and forty-two patients with mild preeclampsia (34.6 %), one hundred and ninety patients who have preeclampsia with severe features (46.2 %), and 79 healthy pregnant controls (19.2 %) were included in the study. Fetal adverse outcomes occurred in 40.1 %, and maternal adverse outcomes only appeared as neurological symptoms in 20.5 % of the preeclampsia patients. Results Healthy controls had significantly lower FIB-4 scores than women with mild preeclampsia, and women with mild preeclampsia had significantly lower FIB-4 scores than women who had preeclampsia with severe features (respectively 0.58±0.29 vs. 0.68±0.44 vs. 1.93±4.92, p=0.003). The FIB-4 scores of preeclampsia patients with neurologic symptoms and preeclampsia patients with fetal adverse events were found to be similar to preeclampsia patients who did not have these problems. In ROC curve analysis, FIB-4 scores ≥0.758 indicated the presence of neurologic symptoms in preeclampsia patients, with a sensitivity of 0.66 and a specificity of 0.66 (p=0.004). Conclusions To the best of our knowledge, this is the first study to establish the FIB-4 scores of preeclampsia patients and determine if FIB-4 scores change with respect to maternal and fetal adverse outcomes. Our findings suggest that FIB-4 might be used to predict pregnancies destined to be complicated with preeclampsia and preeclampsia patients who are more likely to experience maternal and fetal adverse outcomes.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
重度子痫前期的 FIB4 评分增高
摘要 目的 本研究旨在探讨基于四个因素的纤维化指数(FIB-4)在子痫前期中的变化情况,以及FIB-4评分在子痫前期严重程度和胎儿及母体不良结局方面是否存在差异。方法 研究纳入了 142 名轻度子痫前期患者(34.6%)、190 名重度子痫前期患者(46.2%)和 79 名健康孕妇对照组(19.2%)。40.1%的先兆子痫患者出现胎儿不良后果,20.5%的先兆子痫患者仅出现神经系统症状。结果 健康对照组的FIB-4评分明显低于轻度子痫前期妇女,轻度子痫前期妇女的FIB-4评分明显低于重度子痫前期妇女(分别为0.58±0.29 vs. 0.68±0.44 vs. 1.93±4.92,P=0.003)。有神经系统症状的子痫前期患者和有胎儿不良事件的子痫前期患者的FIB-4评分与没有这些问题的子痫前期患者相似。在 ROC 曲线分析中,FIB-4 评分≥0.758 表明子痫前期患者存在神经系统症状,敏感性为 0.66,特异性为 0.66(P=0.004)。结论 据我们所知,这是第一项对子痫前期患者进行 FIB-4 评分并确定 FIB-4 评分是否随母体和胎儿不良结局而变化的研究。我们的研究结果表明,FIB-4 可用于预测子痫前期复杂妊娠,以及更有可能出现母体和胎儿不良结局的子痫前期患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
CXCL12/CXCR4 as a potential axis in diagnosis and predicting disease severity in COVID-19 patients: a new perspective Human estrogen receptor alpha (ERα) targeted cyclic peptides inhibit cell growth and induce apoptosis in MCF-7 cells In vitro and in silico investigations of the pro-apoptotic activity of Opuntia ficus-indica cladode extracts against K562 cells Evaluation of the implementation of the rational use of laboratory tests in the clinical chemistry laboratory Right vagotomy alters heart rate variability temporarily and increases total choline levels in rats
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1